Predictors of clinically significant quality of life impairment in Parkinson's disease
Por:
Garcia, D, Fonticoba, T, Cores, C, Munoz, G, Gonzalez, J, Miro, C, Suarez, E, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, J, Caballol, N, Legarda, I, Vara, J, Cabo, I, Manzanares, L, Aramburu, I, Rivera, M, Catalan, M, Nogueira, V, Puente, V, de Arcos, M, Borrue, C, Vila, B, Sauco, M, Vela, L, Escalante, S, Cubo, E, Padilla, F, Castrillo, J, Alonso, P, Losada, M, Ariztegui, N, Gaston, I, Clavero, P, Kulisevsky, J, Estrada, M, Seijo, M, Martinez, J, Valero, C, Kurtis, M, de Fabregues, O, Ardura, J, Ordas, C, Diaz, L, McAfee, D, Martinez-Martin, P, Mir, P and COPPADIS Study Grp
Publicada:
16 dic 2021
Resumen:
Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months +/- 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 >= 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 +/- 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 +/- 13 to 20.3 +/- 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R-2 = 0.655). An increase in >= 5 and >= 10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.
Filiaciones:
Garcia, D:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Fonticoba, T:
Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain
Cores, C:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Munoz, G:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Gonzalez, J:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Miro, C:
Complejo Hosp Univ A Coruna, CHUAC, La Coruna, Spain
Suarez, E:
Complejo Hosp Univ Ferrol, CHUF, La Coruna, Spain
Jesus, S:
Univ Seville, Unidad Trastornos Movimiento, Serv Neurol & Neurofisiol Clin,CSIC, Inst Biomed Sevilla,Hosp Univ Virgen del Rocio, Seville, Spain
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain
Aguilar, M:
Hosp Univ Mutua Terrassa, Barcelona, Spain
Pastor, P:
Hosp Univ Mutua Terrassa, Barcelona, Spain
Planellas, L:
Clin Pilar, Neurol, Barcelona, Spain
Cosgaya, M:
Hosp Clin Barcelona, Barcelona, Spain
Caldentey, J:
Ctr Neurol Oms 42, Palma de Mallorca, Spain
Caballol, N:
Hosp Moises Broggi, Consorci Sanitari Integral, Barcelona, Spain
Legarda, I:
Hosp Univ Son Espases, Palma De Mallorca, Spain
Vara, J:
Hosp Univ Vall dHebron, Barcelona, Spain
Cabo, I:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain
Manzanares, L:
Hosp Univ La Princesa, Madrid, Spain
Aramburu, I:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain
Hosp Univ Marques de Valdecilla, Santander, Spain
Rivera, M:
Hosp Gen Hospitalet, Consorci Sanitari Integral, Barcelona, Spain
Catalan, M:
Hosp Univ Clin San Carlos, Madrid, Spain
Nogueira, V:
Hosp Costa, Lugo, Spain
Puente, V:
Hosp del Mar, Barcelona, Spain
de Arcos, M:
Hosp Univ Virgen Macarena, Seville, Spain
Borrue, C:
Hosp Infanta Sofia, Madrid, Spain
Vila, B:
Inst Assistencia Sanitaria IAS, Inst Catala Salut, Girona, Spain
:
Hosp Gen Univ Elche, Elche, Spain
Vela, L:
Fdn Hosp Alcorcon, Madrid, Spain
Escalante, S:
Hosp Tortosa Verge de la Cinta HTVC, Tarragona, Spain
Cubo, E:
Complejo Asistencial Univ Burgos, Burgos, Spain
Padilla, F:
Hosp Univ Canarias, San Cristobal La Laguna, Santa Cruz De T, Spain
Castrillo, J:
Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain
Alonso, P:
Hosp Univ Puerta de Hierro, Madrid, Spain
Losada, M:
Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain
Ariztegui, N:
Complejo Hosp Toledo, Toledo, Spain
Gaston, I:
Complejo Hosp Navarra, Pamplona, Spain
Clavero, P:
Complejo Hosp Navarra, Pamplona, Spain
Kulisevsky, J:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Estrada, M:
Hosp Univ Cent Asturias, Oviedo, Spain
Seijo, M:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain
Martinez, J:
Hosp Univ Donostia, San Sebastian, Spain
:
Hosp Arnau Vilanova, Valencia, Spain
Kurtis, M:
Hosp Ruber Int, Madrid, Spain
de Fabregues, O:
Hosp Univ Vall dHebron, Barcelona, Spain
Ardura, J:
Hosp Univ Cabuenes, Gijon, Spain
Ordas, C:
Hosp Rey Juan Carlos, Madrid, Spain
Diaz, L:
Complejo Hosp Univ Orense CHUO, Orense, Spain
McAfee, D:
Univ Penn, Philadelphia, PA 19104 USA
Martinez-Martin, P:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain
Mir, P:
Univ Seville, Unidad Trastornos Movimiento, Serv Neurol & Neurofisiol Clin,CSIC, Inst Biomed Sevilla,Hosp Univ Virgen del Rocio, Seville, Spain
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Alava, Spain
Green Published, gold
|